Overview

A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE)

Status:
Completed

Trial end date:
2021-04-01

Target enrollment:

Participant gender:

Summary

Study KIN-1901-2001 is a multi-center, adaptive, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of gimsilumab in subjects with lung injury or acute respiratory distress syndrome (ARDS) secondary to COVID-19.

Phase:

Phase 2

Details

Lead Sponsor:

Kinevant Sciences GmbH

Collaborator:

Roivant Sciences, Inc.

Treatments:

Gimsilumab